BAGSVÆRD, Denmark, July 31, 2026
Novo Nordisk announced headline results from the Phase 3 ZEUS cardiovascular outcomes trial evaluating ziltivekimab, an investigational IL-6-targeting monoclonal antibody, in more than 6,300 patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and systemic inflammation. Although the once-monthly treatment successfully demonstrated target engagement by significantly reducing free interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hsCRP), the study did not meet its primary endpoint of reducing major adverse cardiovascular events (MACE) compared with placebo. The trial reported a hazard ratio of 0.99 (95% CI: 0.88–1.11), indicating no meaningful reduction in the combined risk of cardiovascular death, non-fatal heart attack, or non-fatal stroke. Despite the disappointing efficacy outcome, Novo Nordisk emphasized that the findings provide valuable scientific insights and reaffirmed its long-term commitment to advancing innovative cardiovascular therapies.
ZEUS Trial Evaluates IL-6 Inhibition in High-Risk Patients
The double-blind, randomized, placebo-controlled Phase 3 ZEUS trial enrolled patients with established ASCVD, CKD, and persistent inflammation defined by hsCRP levels of at least 2 mg/L. Participants received once-monthly subcutaneous ziltivekimab 15 mg or placebo alongside standard-of-care therapy. The primary objective was to determine whether targeting the IL-6 inflammatory pathway could reduce the incidence of major adverse cardiovascular events, a strategy supported by growing evidence linking chronic inflammation to cardiovascular disease progression. While ziltivekimab produced the anticipated biological effects by suppressing inflammatory biomarkers, these changes did not translate into measurable cardiovascular risk reduction, suggesting that IL-6 inhibition alone may not be sufficient to lower MACE risk in this complex patient population.
Safety Profile Remains Consistent Despite Lack of Efficacy
Novo Nordisk reported that the overall incidence of adverse events and serious adverse events was comparable between the ziltivekimab and placebo groups. As expected with IL-6 pathway inhibition, patients receiving ziltivekimab experienced a higher frequency of serious infections, consistent with the known immunomodulatory effects of cytokine-targeted therapies. Importantly, investigators observed no increase in all-cause mortality, and the overall safety findings remained aligned with the drug’s previously established clinical profile. According to the company, the biological activity observed in ZEUS confirms successful inhibition of the intended therapeutic target, even though the desired clinical benefit in cardiovascular event reduction was not achieved.
Advertisement
Novo Nordisk Advances Broader Cardiovascular Development Strategy
Although ZEUS failed to demonstrate cardiovascular outcome benefits, Novo Nordisk stated that the results will not affect its previously announced 2026 adjusted operating profit guidance, aside from a planned non-cash impairment charge in the third quarter of 2026. The company also confirmed that its additional Phase 3 cardiovascular outcome trials, HERMES, evaluating ziltivekimab in heart failure with preserved ejection fraction (HFpEF), and ARTEMIS, assessing the therapy following acute myocardial infarction (AMI), will continue as planned, with topline data expected during the first half of 2027. Full results from the ZEUS study will be presented at an upcoming scientific meeting later in 2026, providing researchers with further insights into the role of IL-6 inhibition in cardiovascular disease and helping guide future development of anti-inflammatory therapeutic strategies.
Source: Novo Nordisk press release
